Retinal Vasculitis Secondary to Durvalumab.
| Autor: | R Andrade A; Ophthalmology Department, Vall d'Hebron, Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain., Moll-Udina A; Ophthalmology Department, Hospital Clínic de Barcelona, Instituto Clínic de Oftalmología, Barcelona, Spain., Martin R; Ophthalmology Department, Vall d'Hebron, Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain., Cilveti E; Ophthalmology Department, Vall d'Hebron, Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain., Subirà O; Ophthalmology Department, Vall d'Hebron, Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain., Disfetano L; Ophthalmology Department, Vall d'Hebron, Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain., García-Arumí J; Ophthalmology Department, Vall d'Hebron, Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Case reports in ophthalmology [Case Rep Ophthalmol] 2020 May 05; Vol. 11 (2), pp. 161-166. Date of Electronic Publication: 2020 May 05 (Print Publication: 2020). |
| DOI: | 10.1159/000507609 |
| Abstrakt: | Ocular manifestations are very rarely reported as side effects to checkpoint inhibitors. We present a case of a 64-year-old Caucasian man in treatment with durvalumab for non-small-cell lung carcinoma who presented a retinal vasculitis with macular edema. After three boluses of methylprednisolone, the retinal vasculitis resolved and macular edema improved during follow-up. There was no need for durvalumab to be withdrawn. Competing Interests: The authors declare no commercial or proprietary conflicts of interest. The authors alone are responsible for the content and writing of the paper. (Copyright © 2020 by S. Karger AG, Basel.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|